Collaboration and License Agreements - Additional Information (Detail) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
|
Jun. 30, 2010
Agreement
|
Jun. 30, 2006 |
Jun. 30, 2019
USD ($)
|
Jun. 30, 2018
USD ($)
|
Jun. 30, 2019
USD ($)
|
Jun. 30, 2018
USD ($)
|
|
| Janssen Pharmaceutical NV [Member] | ||||||
| gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
| Royalty payment | $ 0 | $ 0 | $ 0 | $ 0 | ||
| Accrued royalties | 0 | 0 | 0 | 0 | ||
| Janssen Pharmaceutical NV [Member] | Maximum [Member] | ||||||
| gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
| Percentage of royalty on net sales | 8.00% | |||||
| Janssen Pharmaceuticals, Inc. [Member] | ||||||
| gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
| Number of development and license agreements | Agreement | 2 | |||||
| DiaTex, Inc. [Member] | ||||||
| gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||
| Royalty payment | 0 | 0 | 0 | 0 | ||
| Development payment | $ 0 | $ 0 | $ 0 | $ 0 | ||